reason report
bottom line yesterday market close therav report
oper result total oper loss
ep lower revenu lighter spend
anticip consensu royalti incom gsk sale
trelegi close tripl chronic obstruct pulmonari diseas
copd quarterli global sale
continu believ half therav valu tie
royalti stream current trade level stock
recent pressur due royalti collect partner
withhold therav royalti payment model
updat price target reduc reiter
outperform rate therav stock
revenu primarili continu account
recognit up-front collabor payment yupelri sold
patient product incur loss therav share
book revenu total expens quarter
consensu estim forecast
therav report net loss per share basi
report ep
strong launch trelegi continu global trelegi revenu
mm therav earn
royalti incom report line incom despit non-
payment recal revenu use pay
non-recours note amount year-end
coupon
trelegi royalti legal disput disrupt securit debt
payment therav partner collect royalti
trelegi gsk distribut member partnership
withheld therav earn royalti portion
notifi intend withhold
royalti distribut therav least remaind
therav initi aggress arbitr collect
amount publicli disclos detail reason
disput basi withhold unclear new manag
hedg fund ownership once-friendli partner compani may
concern trajectori royalti payment gsk
asthma product suffer gener competit pressur
trelegi withhold neg impact therav
recent non-recours debt rais securit therav
royalti incom trelegi therav must remit portion royalti
pay interest debt debt agreement allow therav
net debt total capit
dcf use dr tgr
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep quarterli ep may total annual sum due chang share outstand
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
make capit contribut cover shortfal
period therefor therav pressur resolv
legal issu order stay compliant debt
term els payment shortfal ad princip amount
without incur default least octob per debt
agreement disput arbitr agreement
stipul day resolut howev expect protagonist
hedg fund sarissa extort much leverag possibl
situat drag time proceed
much possibl one consid sarissa hold
mp allergan op etc perhap surpris see
resort measur preserv cash valu
tightli control vehicl perceiv risk import compon
valu could act overhang therav stock even
newli commerci respiratori asset continu strong sale
momentum seen partnership develop incept
understand natur agreement respect
royalti remain confid therav ultim prevail
disput secur cash consist partnership term
rate share outperform therav biotechnolog compani form via
spin-out thrx divers set asset robust engin
previous produc sever fda approv drug includ anoro breo vibativ
leverag deep expertis drug deliveri compani late earli stage pipelin
product oper via proven mechanisms-of-act aim differenti either
beneficial/us mode administr revefenacin better safeti /- wider therapeut
window tbph yupelri nebul formul long act
muscarin antagonist lama w/ partner op launch strongli late
approv therav receiv signific share profit product break
even passiv recipi stand earn net royalti
sale gsk close tripl trelegi recent approv us
europ prior medacorp survey work suggest success close tripl could becom
stapl copd standard-of-car model suggest tripl could becom blockbust
opportun temper slower-than-expect launch breo/anoro still
forecast ww tripl sale peak beyond tbph commercial/partn asset
compani also develop improv jak inhibitor jaki partner op
inflammatori bowel diseas ibd norepinephrin serotonin reuptak inhibitor nsri
neurogen orthostat hypotens noh drug leverag novel
deliveri uniqu compound proven mechanisms-of-act could offer superior
safeti and/or treatment effect wider therapeut window
trelegi asthma phase trial hit primari lung function benefit miss exacerb
endpoint late last week partner glaxosmithklin gsk announc headlin result
pivot phase captain studi trelegi versu relvar/breo ellipta uncontrol asthma
trelegi show statist signific benefit lung function measur
improv trough studi primari endpoint howev trelegi result
reduct exacerb statist signific full result
captain present upcom scientif meet therav suggest
exacerb benefit signific consid numer chang signific
believ lack signific exacerb benefit label may caus challeng
payer reimburs access therav suggest full data address
potenti improv sever exacerb time first exacerb could
import data payer negoti
solid yupelri launch underway therav also stand benefit recent launch
nebul long-act muscarin antagonist lama product revefenacin yupelri
formal launch partner op sale disclos either
partner therav share product loss modest
report revenu line product quickli gain market access
avail commerci cover live medicar part live
supplement insur yupelri j-code becom effect juli win formula statu
product month process current formulari cover
institut therav disclos separ institut order yupelri
major academ center total therav disclos patient
prescrib yupelri date repres impress start metric reliabl
descript product launch iqvia data yupelri volum flow
retail channel appear yupelri could start contribut profit end
year ahead expect
quiet data year inhal jak poc come pivot trial event stack
continu enrol patient inflammatori bowel phase ii/iii trial td-
neurogen orthostat hypotens noh phase trial ampreloxetin
none trial report data instead therav present detail data
ampreloxetin phase ii noh studi european neurolog congress enc juli
includ new data on-treat treatment period well chang
patient symptom dizzi score treatment discontinu data help
reinforc therav decis initi phase program dizzi
endpoint one random treat withdraw protocol new clinic data
therav expect report phase investig dri powder inhal pan-jaki td-
data includ safeti biomark data healthi volunt asthma
patient elev nitric oxid level treat day multipl dose
small model updat pt follow updat financi result quarter
manag disclosur commentari updat revenu expens earn
forecast therav decreas revenu forecast
chang later year decreas total oper expens forecast
increas expens ep estim forecast reduc loss
greater loss continu forecast break-even beyond price
target decreas reiter outperform rate therav
estim price target month use dcf analysi discount
rate termin growth rate discount rate consist model
biotech de-risk ph asset multipl program develop
higher risk aldr valuat inclus net cash
investor face multipl risk includ limit
commerci risk gsk trelegi close tripl combin
signific clinic risk earli stage program given stage develop
partnership risk maxim opportun inflammatori bowel
develop risk sinc exploratori phase ii data enter pivot
dilut risk compani need equiti rais opt-in td-
believ could impact stock significantli
loss oper
loss incom tax
provis incom tax
share count period basic dilut
guidanc
svb leerink llc research compani file zack factset consensu
svb leerink llc research compani file zack factset consensu
pipelin program includ current model
pipelin program exclud current
non-ibd indic jak inhibitor
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view
detail phase ii data present mid-year
enrol updat like mid
enrol updat like mid
svb leerink llc research compani file
equival
chang
chg work cap
share outstand includ option warrant
